Top Markets
#1 Helium Helium +94.48%
#2 MowCat MowCat +86.76%
#3 Seeker Seeker +59.16%
#4 UnifAI Network UnifAI Network +33.85%
#5 Tensor Tensor +27.17%
#6 TENDIES TENDIES +26.49%
#7 Pons Pons +22.16%
#8 Zylo Ecosystem Zylo Ecosystem +22.03%
#9 pipedog pipedog +20.60%
#10 Bounce Bounce +19.62%
Coin of the day
Helium Helium
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Gyre Therapeutics, Inc. Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

GYRE
Classificação em ações #11143
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering,... Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Preço da ação
$6.61
Última sincronização: 2026-08-28
Valor de mercado
$736.94M
Variação (1 dia)
-1.05%
Variação (1 ano)
-14.60%
País
US
Negociar Gyre Therapeutics, Inc. (GYRE)

Categoria

Healthcare
Margem Operacional de Gyre Therapeutics, Inc. (GYRE)
Margem Operacional em 2026 TTM: 0.00%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Gyre Therapeutics, Inc., a margem operacional atual (TTM) é 0.00%. No final de 2026, a margem operacional era 0.00%.
Histórico da Margem Operacional da Gyre Therapeutics, Inc. de 2026 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
Não há dados suficientes para as datas fornecidas.
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.